The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
Completed
- Conditions
- Esophageal Cancer
- Registration Number
- NCT05617352
- Lead Sponsor
- Yongtao Han
- Brief Summary
To clarify the effect of Two-field or Three-field Lymphadenectomy on the survival of esophageal squamous cell carcinoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1659
Inclusion Criteria
-
- Men and women aged 18-85 years
-
- Histologically confirmed primary thoracic esophageal squamous cell carcinoma,
-
- Staging PT1b-4A, N0-3, M0 AJCC eighth edition
-
- Excluding lymph node dissection < 15, (meeting the guideline criteria)
-
- The tumor located in the lower middle thoracic.
Exclusion Criteria
-
- Patients with a history of previous thoracic and abdominal surgery that may affect lymphatic reflux
-
- Patients with distant metastasis confirmed by imaging
-
- Patients with obvious surgical contraindications.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of lymph nodes 2010.1.1-2017.12.30 Surgical data were retrospectively collected
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie lymphadenectomy field number impact on esophageal squamous cell carcinoma prognosis?
How does two-field lymphadenectomy compare to three-field in middle/lower thoracic ESCC survival outcomes?
Which biomarkers correlate with improved survival following three-field lymphadenectomy in ESCC patients?
What are the long-term adverse events associated with two-field vs three-field lymphadenectomy in thoracic esophageal cancer?
Are there specific ESCC subtypes where three-field lymphadenectomy demonstrates superior oncologic outcomes compared to standard two-field approaches?
Trial Locations
- Locations (1)
Sichuan Cancer Hospital
🇨🇳Chendu, Sichuan, China
Sichuan Cancer Hospital🇨🇳Chendu, Sichuan, China